1
|
de Sousa ALMD, Dos Santos WM, de Souza ML, Silva LCPBB, Yun AEHK, Aguilera CSB, Chagas BDF, Rolim LA, da Silva RMF, Neto PJR. Layered Double Hydroxides as Promising Excipients for Drug Delivery Purposes. Eur J Pharm Sci 2021; 165:105922. [PMID: 34217802 DOI: 10.1016/j.ejps.2021.105922] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Revised: 06/09/2021] [Accepted: 06/28/2021] [Indexed: 01/20/2023]
Abstract
Layered Double Hydroxides (LDH) have received great attention in the development of drug carrier systems. LDHs have become intelligent excipients of high technological potential for the pharmaceutical industry due to their ability to intercalate biomaterials in the interlayer region, adsorb substances on its vast surface area, have flexible structure, swelling properties, high chemical and thermal stability, modulate drug release, have high biocompatibility and be easily synthesized. This article, using typical examples, mainly addresses the systems formed between LDHs and antimicrobial, antineoplastic and anti-inflammatory agents, which constitute the main pharmacological classes of wide interest due to the problems encountered with low solubility, control in administration, stability in body fluids and toxicity, among others. Additionally, the article also reports on the recent development of ternary or quaternary (multicomponent systems) compounds based on LDH, bringing the advantages of targeted therapy, improving the aqueous stability of nanohybrids and the performance of these inorganic carriers.
Collapse
Affiliation(s)
| | - Widson Michael Dos Santos
- Laboratório de Tecnologia de Medicamentos, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco Brasil
| | - Myla Lôbo de Souza
- Laboratório de Tecnologia de Medicamentos, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco Brasil
| | | | - Adriana Eun He Koo Yun
- Laboratório de Tecnologia de Medicamentos, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco Brasil
| | | | - Beatriz de França Chagas
- Laboratório de Tecnologia de Medicamentos, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco Brasil
| | - Larissa Araújo Rolim
- Central de Análise de Fármacos, Medicamentos e Alimentos, Universidade Federal do Vale do São Francisco (UNIVASF), Petrolina, Pernambuco Brasil
| | | | - Pedro José Rolim Neto
- Laboratório de Tecnologia de Medicamentos, Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco Brasil
| |
Collapse
|
2
|
Lavra ZMM, de Medeiros FPM, da Silva RMF, Rosa TA, Wanderley Sales VDA, Barros Silva LCPB, de Sousa ALMD, de Lima LG, Rolim LA, Neto PJR. Formulation, Development and Scale-Up of Fixed-Dose Combination Tablets Containing Zidovudine, Lamivudine and Nevirapine. Curr HIV Res 2019; 17:360-367. [DOI: 10.2174/1570162x17666190927162155] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Revised: 09/05/2019] [Accepted: 09/12/2019] [Indexed: 12/16/2022]
Abstract
Background:
The development of antiretroviral associations in a single dosage form aims
to ensure improved efficacy, low costs and better adherence to treatment.
Objective:
This work performed the pharmacotechnical development, coating, and stability studies
of fixed-dose combination tablets of zidovudine, lamivudine and nevirapine (300 + 200 + 150 mg,
respectively).
Methods:
Qualitative and quantitative planning of diluents (101 and 250 microcrystalline cellulose,
spray-dried monohydrate lactose and corn starch) and coating polymers (Opadry white II HP® and
Instacoat Aqua Moistshield II®) were analyzed, and direct compression (DC) and wet granulation
(WG) methods were tested aiming the development of the pharmaceutical form. Quality control was
carried out according to the specifications set by official compendia. The chosen formulation was
scaled-up and the industrial batches were submitted to accelerated and long-term stability studies.
Results:
The batches obtained by WG met the requirements, using 101 microcrystalline cellulose,
corn starch and Opadry white II HP®
as excipients. The DC trial was not possible due to the need of
a greater ratio of excipients to improve formulation properties.
Conclusion:
Thus, this study brings a new therapeutic alternative for HIV treatment, contributing to
the development of another possibility to simplify drug administration.
Collapse
Affiliation(s)
- Zênia Maria Maciel Lavra
- Secretariat of Science, Technology and Strategic Inputs - Ministry of Health, Brasilia, DF, Brazil
| | | | - Rosali Maria Ferreira da Silva
- Laboratorio de Tecnologia dos Medicamentos, Department of Pharmaceutical Sciences, Federal University of Pernambuco, Recife-PE, Brazil
| | - Talita Atanazio Rosa
- Laboratorio de Tecnologia dos Medicamentos, Department of Pharmaceutical Sciences, Federal University of Pernambuco, Recife-PE, Brazil
| | | | | | | | | | - Larissa Araújo Rolim
- Pharmacy Collegiate, Federal University of Vale do Sao Francisco, Petrolina-PE, Brazil
| | - Pedro José Rolim Neto
- Laboratorio de Tecnologia dos Medicamentos, Department of Pharmaceutical Sciences, Federal University of Pernambuco, Recife-PE, Brazil
| |
Collapse
|
3
|
Siqueira LDP, Fontes DAF, Aguilera CSB, Timóteo TRR, Ângelos MA, Silva LCPBB, de Melo CG, Rolim LA, da Silva RMF, Neto PJR. Schistosomiasis: Drugs used and treatment strategies. Acta Trop 2017; 176:179-187. [PMID: 28803725 DOI: 10.1016/j.actatropica.2017.08.002] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Revised: 07/29/2017] [Accepted: 08/02/2017] [Indexed: 11/18/2022]
Abstract
Neglected tropical diseases (NTDs) affect millions of people in different geographic regions, especially the poorest and most vulnerable. Currently NTDs are prevalent in 149 countries, seventeen of these neglected tropical parasitic diseases are classified as endemic. One of the most important of these diseases is schistosomiasis, also known as bilharzia, a disease caused by the genus Schistosoma. It presents several species, such as Schistosoma haematobium, Schistosoma japonicum and Schistosoma mansoni, the latter being responsible for parasitosis in Brazil. Contamination occurs through exposure to contaminated water in the endemic region. This parasitosis is characterized by being initially asymptomatic, but it is able to evolve into more severe clinical forms, potentially causing death. Globally, more than 200 million people are infected with one of three Schistosome species, including an estimated 40 million women of reproductive age. In Brazil, about 12 million children require preventive chemotherapy with anthelmintic. However, according to the World Health Organization (WHO), only about 15% of the at-risk children receive regular treatment. The lack of investment by the pharmaceutical industry for the development and/or improvement of new pharmaceutical forms, mainly aimed at the pediatric public, is a great challenge. Currently, the main forms of treatment used for schistosomiasis are praziquantel (PZQ) and oxaminiquine (OXA). PZQ is the drug of choice because it presents as a high-spectrum anthelmintic, used in the treatment of all known species of schistosomiasis and some species of cestodes and trematodes. OXA, however, is not active against the three Schistosome species. This work presents a literature review regarding schistosomiasis. It addresses points such as available treatments, the role of the pharmaceutical industry against neglected diseases, and perspectives for treatment.
Collapse
Affiliation(s)
- Lidiany da Paixão Siqueira
- Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Avenida Professor Artur de Sá, CEP 50740-521, Recife, Pernambuco, Brazil
| | - Danilo Augusto Ferreira Fontes
- Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Avenida Professor Artur de Sá, CEP 50740-521, Recife, Pernambuco, Brazil
| | - Cindy Siqueira Britto Aguilera
- Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Avenida Professor Artur de Sá, CEP 50740-521, Recife, Pernambuco, Brazil
| | - Taysa Renata Ribeiro Timóteo
- Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Avenida Professor Artur de Sá, CEP 50740-521, Recife, Pernambuco, Brazil
| | - Matheus Alves Ângelos
- Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Avenida Professor Artur de Sá, CEP 50740-521, Recife, Pernambuco, Brazil
| | - Laysa Creusa Paes Barreto Barros Silva
- Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Avenida Professor Artur de Sá, CEP 50740-521, Recife, Pernambuco, Brazil
| | - Camila Gomes de Melo
- Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Avenida Professor Artur de Sá, CEP 50740-521, Recife, Pernambuco, Brazil
| | - Larissa Araújo Rolim
- Central de Análise de Fármacos, Medicamentos e Alimentos da Universidade Federal do Vale do São Francisco, Avenida José de Sá Maniçoba, CEP 56304-917, Petrolina, Pernambuco, Brazil
| | - Rosali Maria Ferreira da Silva
- Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Avenida Professor Artur de Sá, CEP 50740-521, Recife, Pernambuco, Brazil
| | - Pedro José Rolim Neto
- Laboratório de Tecnologia dos Medicamentos, Universidade Federal de Pernambuco, Avenida Professor Artur de Sá, CEP 50740-521, Recife, Pernambuco, Brazil.
| |
Collapse
|